SeaStar Medical Provides Updates On Enrollment Of Adult Pivotal Clinical Study And Commercial Launch Of Quelimmune, FDA-Approved In Pediatric Patients
SeaStar Medical Provides Updates On Enrollment Of Adult Pivotal Clinical Study And Commercial Launch Of Quelimmune, FDA-Approved In Pediatric Patients
SeaStar Medical提供成人关键临床研究注册的最新情况，以及获得美国食品药品管理局批准的针对儿科患者的Quelimmune的商业发布
Company plans to hold a business update conference call in April
公司计划在四月份举行业务更新电话会议
DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill patients with AKI.
丹佛，2024年3月12日（GLOBE NEWSWIRE）——SeaStar Medical Holding Corporation（纳斯达克股票代码：ICU）是一家开发专有解决方案以减少重要器官过度炎症影响的商业阶段医疗器械公司（纳斯达克股票代码：ICU），该公司提供了其正在开发的针对AKI危重患者的急性肾损伤（AKI）项目的最新情况。
"We now have 21 subjects enrolled across five clinical sites in our NEUTRALIZE-AKI pivotal clinical trial, which is intended to evaluate the safety and efficacy of our SCD in...
“现在，我们的NEUTRALIZE-AKI关键临床试验在五...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。